SAN DIEGO, Oct. 2 /PRNewswire/ -- Pharmatek Laboratories, Inc., a premier contract development and manufacturing organization supporting the pharmaceutical industry, announced that it is the first CRO on the West Coast to acquire the Xcelodose system, enhancing the company's preclinical and early phase clinical GMP supply capabilities.
"Pharmatek is always looking for ways to move our customers' drug candidates into the clinic more efficiently without compromising quality," said Jeffrey Bibbs, Ph.D., Chief Scientific Officer of Pharmatek Laboratories. "For powder-in-capsule (PIC) applications, the Xcelodose can drastically decrease time to clinic while also lowering the cost of drug product for first-in-human trials."
The Xcelodose, manufactured by Capsugel, a division of Pfizer, is a precision powder micro-doser and automated encapsulator that has the ability to fill formulations or active pharmaceutical ingredient (API) directly into capsules with a remarkable level of accuracy. The Xcelodose can measure to levels as low as 100 micrograms and can dispense into capsules from size 00 to 4. Dosing directly into capsules can reduce the amount of API required. Additionally, the unit reduces overall development time by simplifying analytical and stability protocols.
Pharmatek Laboratories will install the Xcelodose unit in its solid dose manufacturing facility located in San Diego, California. The unit is expected to be validated by mid-October 2009. The company is currently scheduling Xcelodose manufacturing productions for November and December, 2009.
About Pharmatek Laboratories, Inc.
Pharmatek Laboratories, Inc. is a premier pharmaceutical chemistry development company providing full-service pharmaceutical chemistry product development for the pharmaceutical industry. Pharmatek focuses on bringing client compounds from discovery to the clinic with services that include compound selection, analytical development, preformulation testing, formulation development, GMP manufacturing, stability storage and testing, and cytotoxic and high-potency development.
Statements contained in this media release which are not historical facts may constitute forward-looking statements. All forward-looking statements are subject to risks and uncertainties which could cause actual results to differ from those projected including sales forecasts and strategic expansion. The trademarks Pharmatek, Pharmatek Laboratories, Inc., Hot Rod Chemistry, Pharmatek Formulation Screening, Pharmatek University and PTEK U are all property of Pharmatek Laboratories, Inc. Additional information about Pharmatek Laboratories may be obtained at the website http://www.pharmatek.com or by calling 858-805-6383.
Company Contact: Ryan Lane, Marketing Coordinator Pharmatek Laboratories, Inc. (858) 805-6383 x284 email@example.com
SOURCE Pharmatek Laboratories, Inc.
|SOURCE Pharmatek Laboratories, Inc.|
Copyright©2009 PR Newswire.
All rights reserved